Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous mFOLFOX7 Plus Camrelizumab and Apatinib for CNLC Stage III Hepatocellular Carcinoma

NCT05412589 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.

NCT NCT05412589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05412589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous mFOLFOX7 Plus Camrelizumab and Apatinib for CNLC Stage III Hepatocellular Carcinoma
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 2
Overall status
Unknown status
Start date
June 10, 2022
Completion date
July 31, 2026
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii hepatocellular cancer (cnlc staging)